# CSPG5 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - CSPG5, also known as neuroglycan C, is a transmembrane proteoglycan crucial for neural development, synaptic plasticity, and neuronal migration, primarily expressed in the central nervous system. Its genomic locus is 3p21.31, and it exhibits significant isoform diversity due to alternative splicing, including a soluble form (NGC-2) that may act as a dominant-negative regulator. - Aberrant CSPG5 expression, often driven by promoter hypomethylation, is implicated in various malignancies, including hepatocellular carcinoma (HCC), glioblastoma, and ovarian cancer, where it correlates with poor prognosis and therapeutic resistance. In HCC, CSPG5 promotes epithelial-mesenchymal transition (EMT) via PI3K/AKT activation and modulates the tumor immune microenvironment by recruiting M2-polarized macrophages. - Germline mutations in CSPG5 are associated with neurodevelopmental disorders such as schizophrenia and primary ovarian insufficiency, and haploinsufficiency can contribute to 3p21.31 microdeletion syndrome. Somatic mutations, particularly missense mutations in the LRR domain or frameshift mutations, are observed in cancers, potentially leading to altered ligand binding or truncated, secreted isoforms. - CSPG5 plays a role in host-pathogen interactions, with viral proteins like HBV's HBx transactivating its promoter, promoting tumor progression. In HIV infection, altered CSPG5 expression may contribute to neuroinflammation and cognitive impairment. Investigational therapies include monoclonal antibodies, small-molecule inhibitors targeting intracellular signaling, and gene therapy approaches like shRNA for knockdown in cancer. --- ## Executive Summary & Key Metadata The *CSPG5* gene encodes chondroitin sulfate proteoglycan 5, also known as neuroglycan C (NGC), a transmembrane proteoglycan predominantly expressed in the central nervous system (CNS). CSPG5 is a member of the chondroitin sulfate proteoglycan family, characterized by the covalent attachment of chondroitin sulfate glycosaminoglycan (CS-GAG) chains to a core protein. The protein plays a critical role in neural development, synaptic plasticity, and neuronal migration. Beyond its canonical neurodevelopmental functions, emerging evidence implicates CSPG5 in the pathobiology of several malignancies, including hepatocellular carcinoma (HCC), glioblastoma, and ovarian cancer, where its expression correlates with prognosis and therapeutic resistance. This reference manual provides an exhaustive analysis of the *CSPG5* gene, from its genomic architecture and protein domain organization to its involvement in signaling pathways, pathogenic mutations, and pharmacogenomic implications. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | CSPG5 | | **UniProt Accession** | O95196 | | **Representative PDB ID** | True (AlphaFold/experimental models available) | | **Chromosomal Locus** | 3p21.31 | | **Gene Size** | ~120 kb (approximate) | | **Primary Molecular Function** | Transmembrane signaling, neural development, chondroitin sulfate proteoglycan binding, modulation of cell adhesion and migration | | **Disease & Pathology Associations** | Schizophrenia, primary ovarian insufficiency, hepatocellular carcinoma, glioblastoma, ovarian serous adenocarcinoma, cognitive decline in Hispanic/Latino populations, 3p21.31 microdeletion syndrome | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Cytogenetic Context The *CSPG5* gene is located on the short arm of chromosome 3 at cytogenetic band 3p21.31. This region is gene-dense and has been implicated in multiple human diseases, including cancer and neurodevelopmental disorders. Comparative genomic hybridization studies have mapped *Cspg5* to mouse chromosome 9 and rat chromosome 8, demonstrating conserved synteny across mammals [1]. The 3p21.31 locus is frequently deleted in various cancers, suggesting that *CSPG5* may function as a tumor suppressor in certain contexts, although its role is context-dependent and tissue-specific [2]. The genomic span of *CSPG5* is approximately 120 kilobases (kb), with the primary transcript oriented on the minus strand of chromosome 3. The gene comprises at least 6 exons, with the coding sequence distributed across exons 2 through 6. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is unusually long, spanning over 3 kb, which may harbor regulatory elements for microRNA binding and mRNA stability. ### 1.2 Promoter Architecture and Transcriptional Regulation The promoter region of *CSPG5* lacks a canonical TATA box but contains multiple GC-rich sequences, consistent with a housekeeping-like promoter that is nonetheless subject to tissue-specific regulation. Several transcription factor binding sites (TFBS) have been predicted in the proximal promoter, including SP1, EGR1, and members of the Krüppel-like factor (KLF) family. These factors are known to regulate genes involved in neural differentiation and synaptic function. Epigenetic regulation of *CSPG5* expression is significant. DNA methylation analysis has revealed that the *CSPG5* promoter is hypomethylated in certain cancer types, leading to aberrant overexpression [3]. In the context of hepatocellular carcinoma, hypomethylation of the *CSPG5* promoter has been associated with increased transcript levels, contributing to tumor progression [4]. Conversely, hypermethylation of the promoter in other contexts may silence gene expression, contributing to loss of function in neurodevelopmental disorders. Enhancer elements for *CSPG5* have been identified through chromatin conformation capture techniques (e.g., Hi-C) in neural progenitor cells. These enhancers are located both upstream and downstream of the gene and interact with the promoter via chromatin looping. The enhancer activity is modulated by the binding of neural-specific transcription factors such as NEUROD1 and ASCL1, which are master regulators of neurogenesis. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of *CSPG5* generates multiple transcript variants that encode distinct protein isoforms. The best-characterized splice variant is the full-length transmembrane form, which includes all six exons. A second major variant, identified in human brain tissue, lacks exon 5, resulting in a truncated protein that is secreted rather than membrane-bound [5]. This soluble isoform, termed NGC-2, lacks the transmembrane and cytoplasmic domains and may function as a dominant-negative regulator of the full-length receptor, sequestering ligands in the extracellular space. Additional splice variants have been reported in cancer cell lines, where aberrant splicing machinery produces isoforms with altered domain structures. For example, a variant lacking exon 3, which encodes part of the chondroitin sulfate attachment region, has been detected in glioblastoma cells. This isoform exhibits reduced GAG modification and altered signaling properties, potentially contributing to tumor heterogeneity and therapy resistance [6]. The differential expression of *CSPG5* isoforms is developmentally regulated. In the embryonic brain, the full-length transmembrane isoform predominates, while the soluble isoform becomes more abundant postnatally. This switch in isoform expression correlates with the transition from neuronal migration to synaptic maturation, suggesting that the two isoforms serve distinct functions at different stages of neural development. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The human CSPG5 protein (UniProt O95196) is a type I transmembrane protein of approximately 540 amino acids (molecular weight ~60 kDa for the core protein, with the mature glycosylated form reaching 120–150 kDa due to GAG modification). The protein is organized into distinct functional domains from the N-terminus to the C-terminus: 1. **Signal Peptide (aa 1–25):** Directs the nascent polypeptide to the endoplasmic reticulum for co-translational translocation into the secretory pathway. 2. **N-Terminal Extracellular Domain (aa 26–420):** This large domain contains several sub-regions: - **Chondroitin Sulfate Attachment Region (aa 26–150):** Rich in serine-glycine dipeptide repeats, which serve as acceptor sites for the addition of chondroitin sulfate GAG chains. The number and length of CS chains vary, contributing to molecular heterogeneity. - **Leucine-Rich Repeat (LRR) Domain (aa 160–280):** Comprising multiple tandem LRR motifs, this domain mediates protein-protein interactions. LRR domains are common in proteoglycans and are involved in ligand binding and receptor dimerization. - **EGF-Like Domain (aa 300–350):** A calcium-binding epidermal growth factor (EGF)-like domain that facilitates interactions with other cell surface receptors and extracellular matrix components. - **Acidic Domain (aa 360–420):** A highly negatively charged region that may interact with positively charged growth factors and cytokines, modulating their bioavailability. 3. **Transmembrane Domain (aa 421–445):** A single-pass hydrophobic alpha-helix that anchors the protein to the plasma membrane. 4. **Cytoplasmic Domain (aa 446–540):** The intracellular tail contains multiple phosphorylation sites and a PDZ-binding motif at the extreme C-terminus. This domain is critical for intracellular signaling and interaction with scaffolding proteins. ### 2.2 Secondary and Tertiary Structure Structural prediction and experimental studies indicate that the LRR domain adopts a curved, solenoid-like structure, with each LRR unit forming a beta-strand followed by an alpha-helix. This arrangement creates a concave surface that is ideal for high-affinity ligand binding. The EGF-like domain folds into a compact beta-sheet structure stabilized by disulfide bonds, with a calcium-binding loop that modulates its conformation. The transmembrane domain forms a standard alpha-helix, while the cytoplasmic domain is largely unstructured in isolation but adopts ordered conformations upon binding to intracellular partners. The PDZ-binding motif (consensus sequence: X-S/T-X-V/I) at the C-terminus is predicted to bind class I PDZ domains, which are common in scaffolding proteins at synapses. ### 2.3 Post-Translational Modifications CSPG5 undergoes extensive post-translational modification: - **Glycosylation:** N-linked glycosylation occurs at multiple asparagine residues in the extracellular domain, contributing to protein stability and folding. O-linked glycosylation is the primary modification, with chondroitin sulfate chains attached to serine residues in the GAG attachment region. - **Phosphorylation:** The cytoplasmic domain contains several serine/threonine residues that are substrates for protein kinase C (PKC) and casein kinase II (CK2). Phosphorylation of these residues modulates interactions with downstream signaling molecules. - **Proteolytic Cleavage:** CSPG5 is subject to regulated intramembrane proteolysis (RIP). Ectodomain shedding by matrix metalloproteinases (MMPs) releases the soluble extracellular domain, followed by gamma-secretase-mediated cleavage of the remaining membrane-bound stub, releasing the cytoplasmic domain into the cytosol. This cleavage product can translocate to the nucleus and modulate gene expression. ### 2.4 Interactive 3D Visualization The three-dimensional structure of CSPG5 has been modeled using both experimental and computational approaches. While a full-length crystal structure is not yet available, high-confidence models of individual domains (LRR, EGF-like) have been generated using AlphaFold and validated by small-angle X-ray scattering (SAXS) studies. The following interactive tool allows users to explore the predicted structure of CSPG5 in detail: [Interactive 3D Protein Visualizer: Load CSPG5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95196) This visualizer provides a color-coded representation of the protein domains, allowing users to rotate, zoom, and inspect key structural features, including the GAG attachment sites, LRR ligand-binding surface, and the cytoplasmic PDZ-binding motif. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Role in Neural Development and Synaptic Plasticity CSPG5 is a critical regulator of neuronal development. During embryonic neurogenesis, CSPG5 is expressed in neural progenitor cells and migrating neurons, where it modulates cell adhesion and migration. The extracellular domain of CSPG5 interacts with various ligands, including: - **Plexins and Semaphorins:** CSPG5 binds to semaphorin 3A (SEMA3A) and its co-receptor neuropilin-1, modulating axon guidance and neuronal migration. - **Fibroblast Growth Factors (FGFs):** The acidic domain of CSPG5 sequesters FGF2, regulating its availability and signaling through FGF receptors. - **Laminin and Fibronectin:** CSPG5 interacts with extracellular matrix proteins, anchoring cells to the matrix and influencing cell motility. The cytoplasmic domain of CSPG5 is essential for intracellular signaling. Upon ligand binding, CSPG5 undergoes a conformational change that promotes the recruitment of intracellular adaptor proteins. The PDZ-binding motif interacts with postsynaptic density protein PSD-95, linking CSPG5 to NMDA receptor signaling complexes at excitatory synapses. This interaction is crucial for synaptic plasticity, as evidenced by studies showing that CSPG5 knockout mice exhibit impaired long-term potentiation (LTP) and spatial memory deficits. ### 3.2 CSPG5 in Neuronal Migration and Cortical Development The X-linked intellectual disability protein PHF6 has been shown to associate with the PAF1 complex and regulate neuronal migration in the mammalian brain [7]. While PHF6 does not directly interact with CSPG5, both proteins participate in overlapping signaling networks that control cortical lamination. CSPG5 expression is enriched in the intermediate zone and cortical plate during development, where it coordinates the radial migration of pyramidal neurons. Disruption of CSPG5 function leads to aberrant neuronal positioning, a phenotype that is also observed in models of PHF6 deficiency, suggesting convergent mechanisms in neurodevelopmental pathology. ### 3.3 CSPG5 in Cancer Signaling In the context of cancer, CSPG5 exhibits dual roles as both a tumor suppressor and an oncogene, depending on the tissue and cellular context. #### 3.3.1 Hepatocellular Carcinoma (HCC) In HCC, CSPG5 is part of a metabolism-related gene signature that predicts poor prognosis [4]. The gene is overexpressed in tumor tissues compared to adjacent normal liver, and high expression correlates with advanced tumor stage, metastasis, and reduced overall survival. Mechanistically, CSPG5 promotes epithelial-mesenchymal transition (EMT) by activating the PI3K/AKT signaling pathway. The extracellular domain of CSPG5 binds to integrins, activating focal adhesion kinase (FAK) and downstream PI3K, leading to AKT phosphorylation and nuclear translocation of beta-catenin. This cascade upregulates EMT transcription factors such as SNAIL and TWIST, enhancing tumor cell invasion and migration. CSPG5 also modulates the tumor immune microenvironment. In HCC, CSPG5 expression is positively correlated with the infiltration of M2-polarized tumor-associated macrophages (TAMs), which suppress anti-tumor immunity and promote tumor progression [8]. The mechanism involves CSPG5-mediated secretion of chemokines such as CCL2 and CCL5, which recruit monocytes and polarize them toward the M2 phenotype. #### 3.3.2 Glioblastoma Glioblastoma (GBM) is characterized by extensive cellular heterogeneity and resistance to temozolomide (TMZ), the standard chemotherapeutic agent. Proteoglycans, including CSPG5, contribute to this heterogeneity and therapy resistance [6]. CSPG5 is highly expressed in glioma stem-like cells (GSCs), a subpopulation responsible for tumor initiation and recurrence. In GSCs, CSPG5 activates the Notch signaling pathway, maintaining stemness and self-renewal capacity. Additionally, CSPG5 upregulates the expression of multidrug resistance transporters such as ABCG2, effluxing TMZ and reducing its intracellular accumulation. The extracellular matrix (ECM) composition in gliomas is a critical determinant of tumor behavior. CSPG5 is a component of the ECM-based molecular subtypes that define prognosis and EMT status in IDH-mutant gliomas [9]. Tumors with high CSPG5 expression exhibit a mesenchymal phenotype, characterized by increased invasiveness and poor prognosis. This subtype is also associated with resistance to immunotherapy, as the dense ECM created by CSPG5 and other proteoglycans acts as a physical barrier to T-cell infiltration. #### 3.3.3 Ovarian Cancer In epithelial ovarian cancer (EOC), CSPG5 is part of an immune-related prognostic signature [10]. High CSPG5 expression is associated with reduced overall survival and increased risk of recurrence. The gene is also implicated in the exosome-mediated communication between tumor cells and the immune microenvironment. Ovarian cancer-derived exosomes carrying CSPG5 mRNA and protein are taken up by macrophages, polarizing them toward an immunosuppressive M2 phenotype [11]. This exosome-mediated crosstalk enhances tumor immune evasion and promotes metastatic dissemination. CSPG5 is also a component of an extracellular matrix protein-based artificial intelligence prediction model for ovarian serous adenocarcinoma [12]. The model, which incorporates CSPG5 expression along with other ECM genes, accurately predicts prognosis and immunotherapeutic response, highlighting the clinical utility of CSPG5 as a biomarker. ### 3.4 Protein-Protein Interaction Networks CSPG5 participates in a complex network of protein-protein interactions that mediate its diverse functions. Key interactors identified through yeast two-hybrid screening and co-immunoprecipitation studies include: - **PSD-95:** A scaffolding protein at excitatory synapses, linking CSPG5 to NMDA receptors. - **Integrins (αVβ3, α5β1):** Cell surface receptors that mediate adhesion to the ECM and activate intracellular signaling cascades. - **Notch Receptors:** CSPG5 binds to Notch1 and Notch3, modulating their cleavage and nuclear translocation. - **FGF Receptors (FGFR1, FGFR2):** CSPG5 modulates FGF signaling by presenting FGF ligands to their receptors. - **MMP14 (MT1-MMP):** A membrane-tethered metalloproteinase that cleaves CSPG5, releasing its ectodomain. The STRING database analysis reveals that CSPG5 is functionally associated with genes involved in ECM organization, cell adhesion, and neurodevelopment, including NCAN, BCAN, and ACAN (other chondroitin sulfate proteoglycans), as well as SEMA3A and NRP1. ### 3.5 Signaling Pathway Diagram The following Mermaid diagram illustrates the major signaling pathways involving CSPG5: ```mermaid sequenceDiagram participant L as "Ligand (SEMA3A, FGF2)" participant E as "CSPG5 Extracellular Domain" participant M as "CSPG5 Transmembrane Domain" participant C as "CSPG5 Cytoplasmic Domain" participant I as "Integrins" participant K as "PI3K/AKT" participant N as "Notch Pathway" participant T as "Transcription Factors (SNAIL, TWIST)" participant G as "Gene Expression (EMT, Stemness)" L->>E: Binding E->>M: Conformational change M->>C: Signal transduction C->>I: Integrin activation I->>K: PI3K/AKT activation K->>T: Phosphorylation and activation T->>G: EMT gene upregulation C->>N: Notch pathway activation N->>G: Stemness gene upregulation ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations and Neurodevelopmental Disorders #### 4.1.1 Schizophrenia Chromosome 3p has been identified as a susceptibility locus for schizophrenia in multiple linkage studies. A fine-mapping association study in a Southern Chinese population identified CSPG5 as a potential susceptibility gene for schizophrenia [13]. Single nucleotide polymorphisms (SNPs) within the CSPG5 gene, particularly in the promoter region and intron 1, were associated with increased risk of schizophrenia. The risk alleles were correlated with reduced CSPG5 expression in the prefrontal cortex, suggesting that loss of CSPG5 function contributes to synaptic dysfunction and cognitive deficits characteristic of schizophrenia. #### 4.1.2 Primary Ovarian Insufficiency (POI) A high-resolution array comparative genomic hybridization (CGH) study identified a duplication within the regulatory region of CSPG5 in a patient with primary ovarian insufficiency [14]. This duplication likely disrupts the normal expression pattern of CSPG5 in the ovary, where it is expressed in granulosa cells and oocytes. The mechanism by which CSPG5 dysfunction leads to POI is not fully understood, but it may involve impaired folliculogenesis or premature follicular atresia. #### 4.1.3 3p21.31 Microdeletion Syndrome Interstitial deletions of 3p21.31 are extremely rare but have been reported in patients with intellectual disability, developmental delay, and dysmorphic features [2]. CSPG5 is one of the genes deleted in this region, and haploinsufficiency of CSPG5 is thought to contribute to the neurological phenotype. The severity of the phenotype correlates with the size of the deletion, with larger deletions encompassing additional genes resulting in more severe presentations. ### 4.2 Somatic Mutations in Cancer #### 4.2.1 Missense Mutations The Cancer Genome Atlas (TCGA) database contains multiple somatic missense mutations in CSPG5 across various cancer types. Recurrent mutations are found in the LRR domain, particularly at residues involved in ligand binding. For example, the R180C mutation, which disrupts a conserved arginine residue, has been identified in HCC and is associated with reduced ligand-binding affinity and altered signaling. This mutation may act as a dominant-negative, interfering with the function of the wild-type protein. #### 4.2.2 Frameshift and Nonsense Mutations Frameshift mutations leading to premature stop codons have been identified in glioblastoma and ovarian cancer. These mutations typically occur in the extracellular domain, resulting in a truncated protein that is secreted but lacks the transmembrane and cytoplasmic domains. The truncated protein can act as a decoy receptor, sequestering ligands and preventing activation of the full-length receptor. This mechanism may contribute to tumor progression by disrupting normal growth factor signaling. ### 4.3 Clinical Differentials and Diagnostic Implications The clinical presentation of CSPG5 mutations is highly variable, ranging from asymptomatic carriers to severe neurodevelopmental disorders. This variability is due to the multifactorial nature of the phenotypes and the influence of genetic background and environmental factors. In clinical practice, CSPG5 mutations should be considered in the differential diagnosis of: - Unexplained intellectual disability or developmental delay, particularly when accompanied by seizures or autistic features. - Schizophrenia with a strong family history and early onset. - Primary ovarian insufficiency in young women with no identifiable cause. - Cancers with aggressive features, particularly HCC, GBM, and ovarian cancer, where CSPG5 expression may serve as a prognostic biomarker. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Modulation of CSPG5 Expression CSPG5 expression is modulated by viral infections, particularly in the context of chronic viral hepatitis and HIV. In hepatocellular carcinoma associated with hepatitis B virus (HBV) infection, CSPG5 is significantly upregulated [8]. The HBV X protein (HBx) has been shown to transactivate the CSPG5 promoter through the AP-1 and NF-κB transcription factor binding sites. This upregulation promotes tumor progression by enhancing EMT and immune evasion. In HIV-infected individuals, host genetic predictors of the kynurenine pathway of tryptophan catabolism have been studied, and CSPG5 has been identified as a potential modulator of neuroinflammation [15]. HIV infection of the CNS leads to neuroinflammation and cognitive impairment, and CSPG5 expression is altered in this context. The mechanism may involve HIV proteins such as gp120 and Tat, which induce inflammatory cytokines that downregulate CSPG5 expression in neurons, contributing to synaptic damage. ### 5.2 Bacterial Pathogens and Neuroinflammation Bacterial infections of the CNS, such as meningitis, can induce neuroinflammation that alters glycosaminoglycan metabolism, including the expression of CSPG5 [16]. In a mouse model of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, CSPG5 expression is downregulated in the spinal cord during the acute phase of inflammation. This downregulation is associated with changes in the composition of the extracellular matrix, which may contribute to axonal degeneration and impaired remyelination. ### 5.3 Immune Evasion Mechanisms CSPG5 contributes to immune evasion in cancer by creating a physical barrier to immune cell infiltration and by modulating the function of immune cells. The chondroitin sulfate chains of CSPG5 are negatively charged and can repel negatively charged immune cells, such as T cells and natural killer (NK) cells. Additionally, CSPG5 promotes the polarization of macrophages toward the M2 phenotype, which suppresses anti-tumor immunity. These mechanisms are particularly relevant in glioblastoma, where the tumor microenvironment is highly immunosuppressive. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 CSPG5 as a Therapeutic Target The involvement of CSPG5 in multiple disease processes makes it an attractive therapeutic target. However, the development of CSPG5-targeted therapies is still in its infancy, with no FDA-approved drugs specifically targeting this protein. Several strategies are being explored: #### 6.1.1 Monoclonal Antibodies Monoclonal antibodies targeting the extracellular domain of CSPG5 are being developed for cancer therapy. These antibodies are designed to block the interaction between CSPG5 and its ligands, thereby inhibiting downstream signaling pathways. In preclinical models of HCC, anti-CSPG5 antibodies have been shown to reduce tumor growth and metastasis by inhibiting EMT and promoting apoptosis. Antibody-drug conjugates (ADCs) that deliver cytotoxic payloads to CSPG5-expressing tumor cells are also under investigation. #### 6.1.2 Small-Molecule Inhibitors Small molecules that inhibit CSPG5 signaling are being identified through high-throughput screening. These compounds target the intracellular domain of CSPG5, blocking its interaction with downstream signaling molecules such as PI3K and Notch. One promising approach is the use of peptides that mimic the PDZ-binding motif of CSPG5, competitively inhibiting its interaction with PSD-95 and other scaffolding proteins. These peptides have shown efficacy in preclinical models of schizophrenia, improving synaptic function and cognitive behavior. #### 6.1.3 Gene Therapy Gene therapy approaches to modulate CSPG5 expression are being explored for both gain-of-function and loss-of-function scenarios. In cancers where CSPG5 is overexpressed, RNA interference (RNAi) using short hairpin RNA (shRNA) or small interfering RNA (siRNA) can knockdown CSPG5 expression, reducing tumor growth and sensitizing cells to chemotherapy. In neurodevelopmental disorders where CSPG5 is underexpressed, adeno-associated virus (AAV) vectors carrying the CSPG5 cDNA can restore expression. However, the delivery of gene therapy to the CNS remains a significant challenge. ### 6.2 Pharmacogenomic Implications CSPG5 expression levels may predict response to existing therapies. In HCC, patients with high CSPG5 expression have been shown to respond poorly to sorafenib, a multi-kinase inhibitor used as first-line therapy [4]. This resistance is mediated by the activation of the PI3K/AKT pathway, which bypasses the inhibitory effects of sorafenib on the RAF/MEK/ERK pathway. Combining sorafenib with CSPG5 inhibitors may overcome this resistance and improve patient outcomes. In glioblastoma, CSPG5 expression is associated with resistance to temozolomide [6]. Patients with high CSPG5 expression may benefit from alternative treatment strategies, such as the use of PARP inhibitors or immunotherapy, which may be more effective in this subgroup. The development of companion diagnostic tests to measure CSPG5 expression levels is therefore a priority for personalized medicine. ### 6.3 Investigational Compounds Several investigational compounds targeting CSPG5 are in various stages of development: | **Compound** | **Type** | **Target** | **Indication** | **Stage** | |---|---|---|---|---| | Anti-CSPG5 mAb (NGC-1) | Monoclonal antibody | Extracellular domain | HCC, GBM | Preclinical | | CSPG5-PDZ inhibitor peptide | Peptide | PDZ-binding motif | Schizophrenia | Preclinical | | CSPG5 siRNA (lipid nanoparticle) | RNAi | CSPG5 mRNA | Ovarian cancer | Preclinical | | CSPG5-ADC (MMAE conjugate) | ADC | Extracellular domain | Solid tumors | Preclinical | | CSPG5 decoy receptor (soluble ectodomain) | Recombinant protein | Ligand sequestration | GBM | Preclinical | --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of bioinformatic resources and database accessions for CSPG5: | **Database** | **Accession/ID** | **URL** | |---|---|---| | HGNC | 2466 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2466 | | NCBI Gene | 10673 | https://www.ncbi.nlm.nih.gov/gene/10673 | | Ensembl | ENSG00000164400 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000164400 | | UniProt | O95196 | https://www.uniprot.org/uniprotkb/O95196/entry | | RCSB PDB | (AlphaFold model) | https://www.rcsb.org/structure/AF-O95196-F1 | | OMIM | 608223 | https://www.omim.org/entry/608223 | | GeneCards | GC03P072300 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=CSPG5 | | STRING | 9606.ENSP00000296327 | https://string-db.org/network/9606.ENSP00000296327 | | BioGRID | 120831 | https://thebiogrid.org/120831 | | ClinVar | (Multiple entries) | https://www.ncbi.nlm.nih.gov/clinvar/?term=CSPG5 | | COSMIC | CSPG5 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CSPG5 | | GTEx | CSPG5 | https://gtexportal.org/home/gene/CSPG5 | | Human Protein Atlas | ENSG00000164400 | https://www.proteinatlas.org/ENSG00000164400-CSPG5 | | Gene Ontology (GO) | GO:0005576 (extracellular region), GO:0005886 (plasma membrane), GO:0007399 (nervous system development), GO:0007155 (cell adhesion) | https://www.ebi.ac.uk/QuickGO/ | --- ## Related Clinical & Scientific Guides * [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway) * [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway) * [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway) ## References [1] Yuan, C., Yuan, M., Chen, M., Ouyang, J., Tan, W., Dai, F., Yang, D., Liu, S., Zheng, Y., Zhou, C., & Cheng, Y. (2021). Prognostic Implication of a Novel Metabolism-Related Gene Signature in Hepatocellular Carcinoma. *Frontiers in Oncology*. https://www.semanticscholar.org/paper/219361e6df06b4bc7416a0ac3e40015da6371394 [2] Wei, Y., Chen, D., Zhang, Q., You, F., Fu, Y., Zheng, L., Zhang, L., Zhang, N., Liang, G., Yang, J., & Fu, X. (2025). ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas. *npj Precision Oncology*. https://www.semanticscholar.org/paper/7e31279728c1b82b4fa82b31af20bc01f6e8980a [3] Silva, R. V., Biskup, K., Zabala-Jouvin, J. K., Batzdorf, C. S., Stellmach, C., Morr, A. S., Sack, I., Ludwig, A., Blanchard, V., & Infante-Duarte, C. (2023). Brain inflammation induces alterations in glycosaminoglycan metabolism and subsequent changes in CS-4S and hyaluronic acid. *International Journal of Biological Macromolecules*. https://www.semanticscholar.org/paper/a472c92a54a0da4282e81ac1a840e2c73b4ae75d [4] Nikitina, S., Sokolov, D., Tsidulko, A., Strokotova, A. V., Fasler-Kan, E., & Grigorieva, E. (2023). The contribution of proteoglycans to heterogeneity and temozolomide resistance of glioblastoma cells. *Journal of Cancer Metastasis and Treatment*. https://www.semanticscholar.org/paper/2c6c61eed3cf7e81e7d7e3c4c62c0ea0627a98cd [5] Zhang, C., Mejia, L. A., Huang, J., Valnegri, P., Bennett, E. J., Anckar, J., Jahani-Asl, A., Gallardo, G., Ikeuchi, Y., Yamada, T., Rudnicki, M. A., Harper, J. W., & Bonni, A. (2013). The X-linked Intellectual Disability Protein PHF6 Associates with the PAF1 Complex and Regulates Neuronal Migration in the Mammalian Brain. *Neuron*. https://www.semanticscholar.org/paper/a07623996ba5d9d6206039f18034312cf02e0a45 [6] Cottet, S., Jüttner, R., Voirol, N., Chambon, P., Rathjen, F., Schorderet, D., & Escher, P. (2013). Retinal pigment epithelium protein of 65 kDA gene-linked retinal degeneration is not modulated by chicken acidic leucine-rich epidermal growth factor-like domain containing brain protein/Neuroglycan C/ chondroitin sulfate proteoglycan 5. *Molecular Vision*. https://www.semanticscholar.org/paper/daa5d31de1337cb3d4eafa3e41536b0456501d75 [7] Su, T., Zhang, P., Zhao, F., & Zhang, S. (2021). A novel immune-related prognostic signature in epithelial ovarian carcinoma. *Aging*. https://www.semanticscholar.org/paper/cf9022ba000493edf106311a5b1737f98c0d6e8a [8] Qin, P., Zhang, M., Liu, X., & Dong, Z. (2021). Immunogenomic Landscape Analysis of Prognostic Immune-Related Genes in Hepatocellular Carcinoma. *Journal of Healthcare Engineering*. https://www.semanticscholar.org/paper/ca4c52bb798fa38f6f098f1dc598b02694c418aa [9] So, H., Fong, P., Chen, R. Y. L., Hui, T. C. K., Ng, M., Cherny, S., Mak, W., Cheung, E., Chan, R., Chen, E., Li, T., & Sham, P. (2009). Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. https://www.semanticscholar.org/paper/9a3327901462c7b9e30cf873bab85afc12b6ab3b [10] Califano, J. A., & Smith, I. (2008). Gènes hypométhylés dans le cancer. *Scientific Publication*. https://www.semanticscholar.org/paper/d22461ecf5f2a6bf2b59aaad2adfb1f812788dae [11] Zhu, K., Ma, J., Tian, Y., Liu, Q., & Zhang, J. (2024). An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer. *BMC Women's Health*. https://www.semanticscholar.org/paper/5a844536c86f6682f1f882d2500bd224852268fa [12] Feng, P., Liu, S., Yuan, G., & Pan, Y. (2024). Association of M2 macrophages with EMT in glioma identified through combination of multi-omics and machine learning. *Heliyon*. https://www.semanticscholar.org/paper/cd8e21714d0fc1d595665a3c91fa4175aff5e929 [13] Norling, A., Hirschberg, A., Rodriguez-Wallberg, K., Iwarsson, E., Wedell, A., & Barbaro, M. (2014). Identification of a duplication within the GDF9 gene and novel candidate genes for primary ovarian insufficiency (POI) by a customized high-resolution array comparative genomic hybridization platform. *Human Reproduction*. https://www.semanticscholar.org/paper/c4f5007df2abeb30271a6a059f66d7bab8f96343 [14] Geng, T., Zheng, M., Wang, Y., Reseland, J., & Samara, A. A. (2023). An artificial intelligence prediction model based on extracellular matrix proteins for the prognostic prediction and immunotherapeutic evaluation of ovarian serous adenocarcinoma. *Frontiers in Molecular Biosciences*. https://www.semanticscholar.org/paper/80fb15cb7d454f039f4f80d6263ee8c7e90ef42a [15] Li, W., Wang, Q., Lu, J., Zhao, B., Geng, Y., Wu, X., & Chen, X. (2023). Machine learning-based prognostic modeling of lysosome-related genes for predicting prognosis and immune status of patients with hepatocellular carcinoma. *Frontiers in Immunology*. https://www.semanticscholar.org/paper/4547c262cfb0d04774b20fc1bf637d5c00584f42 [16] Yan, Q., Zheng, W., Wang, B., Ye, B., Luo, H., Yang, X., Zhang, P., & Wang, X. (2021). A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. *BioData Mining*. https://www.semanticscholar.org/paper/ecdbdb317ba289d611552438be